Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Current Leases (2016 - 2025)

Ligand Pharmaceuticals' Current Leases history spans 14 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Current Leases fell 13.51% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, down 13.51%, while the annual FY2025 figure was $1.1 million, 13.51% down from the prior year.
  • Current Leases for Q4 2025 was $1.1 million at Ligand Pharmaceuticals, up from $1.1 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.6 million in Q2 2022 and bottomed at $3000.0 in Q1 2024.
  • The 5-year median for Current Leases is $769500.0 (2023), against an average of $863777.8.
  • The largest annual shift saw Current Leases plummeted 98.96% in 2023 before it surged 28533.33% in 2025.
  • A 5-year view of Current Leases shows it stood at $46000.0 in 2021, then soared by 1356.52% to $670000.0 in 2022, then tumbled by 98.96% to $7000.0 in 2023, then surged by 17985.71% to $1.3 million in 2024, then dropped by 13.51% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Current Leases are $1.1 million (Q4 2025), $1.1 million (Q3 2025), and $24000.0 (Q2 2025).